Want to see SE:NXTCL full AI Analyst Report?

NextCell Pharma AB (NXTCL) Price & Analysis

1 Followers

NXTCL Stock Chart & Stats

kr0.92

kr0.02(0.56%)

At close: Mar 06 4:00 PM EST

kr0.92

kr0.02(0.56%)

Day’s Range― - ―

52-Week Rangekr0.63 - kr1.78

Previous CloseN/A

Volume77.06K

Average Volume (3M)237.08K

Market Cap

kr126.39M

Enterprise Valuekr107.45

Total Cash (Recent Filing)kr32.33M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.35

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding126,392,960

10 Day Avg. Volume155,192

30 Day Avg. Volume237,081

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.4

Revenue Forecast (FY)kr12.00M

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetThe absence of debt limits interest obligations and refinancing risk, giving NextCell greater flexibility while it develops therapies. This conservative capital structure is a durable support, although it does not resolve the company’s need for operating funding.

Multi-Year Revenue GrowthThe multi-year increase indicates that NextCell has expanded revenue compared with its earlier base, supporting potential commercial traction in its therapies and services. However, the durability of this trend depends on reversing the latest TTM decline.

Cell Therapy PlatformNextCell’s focus on mesenchymal stromal cell therapies, together with cell banking and manufacturing capabilities, provides a specialized platform across development and related services. These capabilities may support future pipeline and partnership opportunities.

Bears Say

Persistent Cash BurnSustained negative operating and free cash flow means the business cannot currently fund operations internally. Continued development therefore depends on external financing, creating long-term execution risk and possible dilution even with no debt.

Deep UnprofitabilityPersistent losses and negative gross margins show that NextCell has not yet demonstrated an economically viable operating model. Until products or services generate stronger contribution, additional investment may continue to weigh on earnings and capital efficiency.

Equity ErosionThe substantial reduction in equity reflects accumulated losses and cash consumption, weakening the company’s financial cushion. This increases reliance on future capital raises and creates a durable risk of shareholder dilution if funding needs persist.

NXTCL FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was kr0.63 and its highest was kr1.78 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is kr126.39M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is Aug 27, 2026 which is in 7 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on May 28, 2026. The company reported -kr0.092 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 126,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -kr0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.206%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in SE:NXTCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.